Free Trial

Cartesian Therapeutics Q3 2023 Earnings Report

Cartesian Therapeutics logo
$19.02 -0.25 (-1.30%)
(As of 12/20/2024 05:16 PM ET)

Cartesian Therapeutics EPS Results

Actual EPS
-$1.20
Consensus EPS
-$1.05
Beat/Miss
Missed by -$0.15
One Year Ago EPS
N/A

Cartesian Therapeutics Revenue Results

Actual Revenue
$6.55 million
Expected Revenue
$9.70 million
Beat/Miss
Missed by -$3.15 million
YoY Revenue Growth
N/A

Cartesian Therapeutics Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

Cartesian Therapeutics Earnings Headlines

Cartesian Therapeutics (NASDAQ:RNAC) Coverage Initiated at BTIG Research
Cartesian Therapeutics initiated with a Buy at BTIG
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
See More Cartesian Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cartesian Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cartesian Therapeutics and other key companies, straight to your email.

About Cartesian Therapeutics

Cartesian Therapeutics (NASDAQ:RNAC), a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

View Cartesian Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings